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Abstract: New Vinca alkaloid derivatives were synthesized to improve the biological activity of
the natural alkaloid vindoline. To this end, experiments were performed to link vindoline with
various structural units, such as amino acids, a 1,2,3-triazole derivative, morpholine, piperazine and
N-methylpiperazine. The structure of the new compounds was characterized by NMR spectroscopy
and mass spectrometry (MS). Several compounds exhibited in vitro antiproliferative activity against
human gynecological cancer cell lines with IC50 values in the low micromolar concentration range.
Keywords: organic synthesis; anticancer drugs; Vinca alkaloids; vindoline; pharmacophores;
IC50 values
1. Introduction
The famous Vinca alkaloid family was isolated first in the 1950s from the leaves of
Catharanthus roseus. Some of these natural compounds, along with their semisynthetic analogues,
are still being used as chemotherapeutic agents in anticancer therapy (especially in the case of
lymphomas and leukemia) [1–15]. Vindoline (1) and catharanthine (2) are the two subunits of the
“dimeric” alkaloids vinblastine (3) and vincristine (4), which are remarkable representatives of the
Vinca family with a significant cytotoxic activity (Figure 1). Vindoline (1) is present in the plant in
a much larger quantity than the dimers, however, it does not have any anticancer effect.
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effects (e.g., toxicity and multidrug-resistance). Therefore, we have attempted to test vindoline (1) as 
a potential antitumor agent by connecting it to different natural and synthetic pharmacophores. 
Accordingly, our main purpose was to test the idea that not only vinblastine (3) and vincristine 
(4), but a “monomer” Vinca alkaloid unit could also have anticancer activity, when it is combined 
with certain structural units. 
 
Figure 1. Vindoline (1), catharanthine (2), vinblastine (3), and vincristine (4) as representatives of the 
well-known Vinca alkaloid family. 
Vinca alkaloids are usually used in the form of sulfate salts and are administered via intravenous 
injection in clinical therapy since their absorption is poor from the gastrointestinal tract. Their most 
significant adverse effects are neurotoxicity (peripheral neuropathy) and myelosuppression. Besides 
their significant toxicity, multidrug-resistance (MDR) is another problem that restricts the 
applicability of these pharmaceutical molecules in clinical therapy. Therefore, the basic aim of our 
research project was to synthesize new Vinca alkaloid derivatives in order to increase their 
effectiveness and/or reduce their serious side effects. 
There are several pharmaceuticals on the market, which include the pharmacophores that we 
wished to introduce. 1,2,3-triazole is a widely used moiety in modern drug discovery due to its 
advantageous structural properties (e.g., moderate dipole character, rigidity, in vivo metabolic 
stability and the ability to forma hydrogen bond, which increases water solubility) as a potential 
connecting unit. Furthermore, this particular azaheterocycle has several beneficial biological 
activities, such as anticancer, antifungal and antibacterial effects. There are also HIV protease and 
histone deacetylase inhibitors on the market, which include 1,2,3-triazole. These compounds can be 
easily synthesized via click chemistry, which is an increasingly used method in medicinal chemistry 
[16,17]. Other nitrogen-containing heterocycles, such as piperazine and morpholine could also have 
significant therapeutic value [18]. Piperazine analogues show diverse biological activities (e.g., 
antimalarial, antipsychotic, and antidepressant), too. Finally, morpholine derivatives also have 
outstanding pharmaceutical applications as anti-inflammatory, analgesic, neuroprotective, or 
antitumor agents, just to mention a few examples. The wide spectrum of biological utilities that these 
molecules offer made it clear that it is worthwhile to try these pharmacophores within the Vinca 
alkaloid family. 
Recently, several experiments were performed to conjugate Vinca alkaloids with different types 
of amino acid esters, steroids and triphenylphosphine [19–24]. The advantage of linking with amino 
acids is that the given products, bound to carrier peptides (e.g., octaarginine), are able to enter directly 
into the cancer cells, thereby enabling more targeted therapy, and thus reducing the mentioned 
serious side effects. On the other hand, the steroid vector can facilitate the internalization of the drug 
into the cell. Finally, a triphenylphospine unit could help Vinca compounds to fight against multidrug 
resistance and promote the accumulation of the drug inside cancer cells. Moreover, it has antitumor 
activity on its own [25]. The products obtained showed promising half maximal inhibitory 
concentration (IC50) values [19–21], or were measured across the entire NCI cell panel and had 
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Recently, a development program has been started aiming at the synthesis of special complex
molecules by incorporating two drug pharmacophores into one single molecule so as to obtain selective
anticancer drugs. The objective of this project is to make available new derivatives of Vinca alkaloids
that could serve as alternatives to vinblastine (3) and vincristine (4), which have a favorable antitumor
effect, however, also have a high molecular weight, low absorption and several unwanted effects (e.g.,
toxicity and multidrug-resistance). Therefore, we have attempted to test vindoline (1) as a potential
antitumor agent by connecting it to different natural and synthetic pharmacophores.
Accordingly, our main purpose was to test the idea that not only vinblastine (3) and vincristine
(4), but a “monomer” Vinca alkaloid unit could also have anticancer activity, when it is combined with
certain structural units.
Vinca alkaloids are usually used in the form of sulfate salts and are administered via
intravenous injection in clinical therapy since their absorption is poor from the gastrointestinal tract.
Their most significant adverse effects are neurotoxicity (peripheral neuropathy) and myelosuppression.
Besides their significant toxicity, multidrug-resistance (MDR) is another problem that restricts the
applicability of these pharmaceutical molecules in clinical therapy. Therefore, the basic aim of our
research project was to synthesize new Vinca alkaloid derivatives in order to increase their effectiveness
and/or reduce their serious side effects.
There are several pharmaceuticals on the market, which include the pharmacophores that
we wished to introduce. 1,2,3-triazole is a widely used oiety in modern drug discovery due to
its advantageous structural properties (e.g., moderate dipole character, rigidity, in vivo metabolic
stability and the ability to forma hydrogen bond, which increases water solubility) as a potential
connecting unit. Furthermore, this particular azaheterocycle has several beneficial biological activities,
such as anticancer, antifungal and antibacterial effects. There are also HIV protease and histone
deacetylase inhibitors on the market, which include 1,2,3-triazole. These compounds can be easily
synthesized via click chemistry, which is an increasingly used method in medicinal chemistry [16,17].
Other nitrogen-containing heterocycles, such as piperazine and morpholine could also have significant
therapeutic value [18]. Piperazine analogues show diverse biological activities (e.g., antimalarial,
antipsychotic, and antidepressant), too. Finally, morpholine derivatives also have outstanding
pharmaceutical applications as anti-inflammatory, analgesic, neuroprotective, or antitumor agents,
just to mention a few examples. The wide spectrum of biological utilities that these olecules offer
made it clear that it is worthwhile to try these pharmacophores within the Vinca alkaloid family.
Recently, several experiments were performed to conjugate Vinca alkaloids with different types of
amino acid esters, steroids and triphenylphosphine [19–24]. The advantage of linking with amino acids
is that the given products, bound to carrier peptides (e.g., octaarginine), are able to enter directly into
the cancer cells, thereby enabling more targeted therapy, and thus reducing the mentioned serious side
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effects. On the other hand, the steroid vector can facilitate the internalization of the drug into the cell.
Finally, a triphenylphospine unit could help Vinca compounds to fight against multidrug resistance
and promote the accumulation of the drug inside cancer cells. Moreover, it has antitumor activity
on its own [25]. The products obtained showed promising half maximal inhibitory concentration
(IC50) values [19–21], or were measured across the entire NCI cell panel and had promising in vitro
cytotoxic activities (in terms of growth percent rates (GPR) and growth inhibition of 50% of cells (GI50)
values) [22–24], according to the National Institutes of Health (NIH), US [26–29].
2. Results and Discussion
2.1. Preparation of Vindoline Derivatives Coupled to (l)- and (d)-Tryptophan Methylester
2.1.1. Starting from 10-Aminovindoline (5) with Succinic Anhydride
The amino acid-conjugated vindoline derivatives (7 and 8) that we aimed at were achieved
after the synthesis of 10-aminovindoline (5), known in the literature [30] (Scheme 1). Derivative 5
was N-acylated with succinic anhydride in dry toluene at 80 ◦C yielding compound 6, which was
then coupled with (l)- and (d)-tryptophan methylester. The amidation of compound 6 with the
mentioned amino acid esters was performed in the presence of N,N’-dicyclohexylcarbodiimide (DCC)
in dichloromethane (DCM) initially at 0 ◦C, and was then continued at room temperature. The expected
products (7 and 8) were obtained in yields of 63% and 27%, respectively.
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Scheme 1. N-acylation of 10-aminovindoline (5) with succinic anhydride and the amidation of 
compound 6 with (L)- and (D)-tryptophan methyl ester. 
2.1.2. Starting from 17-desacetylvindoline (9) with Succinic Anhydride  
The target amino acid-conjugated vindoline derivatives (11 and 12) were synthesized from 
compound 10 [31] derived by the reaction of 17-desacetylvindoline (9) [31] with succinic anhydride 
(Scheme 2). Compound 10 could be coupled with (L)- and (D)-tryptophan methylester (see below). 
The amidations afforded products 11 and 12 in yields of 61% and 48%, respectively. 
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2.1.2. Starting from 17-Desacetylvindoline (9) with Succinic Anhydride
The target amino acid-conjugated vindoline derivatives (11 and 12) were synthesized from
compound 10 [31] derived by the reaction of 17-desacetylvindoline (9) [31] with succinic anhydride
(Scheme 2). Compound 10 could be coupled with (l)- and (d)-tryptophan methylester (see below).
The amidations afforded products 11 and 12 in yields of 61% and 48%, respectively.
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Scheme 2. The amidation of compound 10 and (L)- and (D)-tryptophan methyl ester. 
2.1.3. Starting from 10-Aminovindoline (5) with Chloroacethyl Chloride  
10-Aminovindoline (5) was N-acylated with chloroacethyl chloride, giving 10-
chloroacethamido-vindoline (13, 63%), which was then coupled with (L)- and (D)-tryptophan 
methylester to afford the expected conjugated derivatives (14, 15) in yields of 22% and 21%, 
respectively (Scheme 3). 
 
Scheme 3. N-Alkylation of (L)- and (D)-tryptophan methylester with 10-chloroacetamido-vindoline 
(13). 
2.2. Preparation of Vindoline Derivatives Coupled to a 1,2,3-Triazole Moiety 
2.2.1. Click Reaction Using Linker Between the two Pharmacophores 
The first step was the preparation of the 4-oxo-4-(prop-2-ynyloxy)butanoic acid (16) known in 
the literature [32]. This compound (16) could be connected to 17-desacetylvindoline (9) in the 
presence of N,N’-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) in 
dichloromethane (DCM), affording compound 17 in 34% yield. Compound 17 was coupled with 4-
fluorobenzyl-azide (18) [17] utilizing the widely known copper-catalyzed click chemistry [16]. The 
reaction was performed in the presence of triphenylphosphine, copper(I) iodide and N,N-
diisopropylethylamine (DIPEA) in toluene under reflux to provide the expected conjugated product 
(19) in a yield of 24%, containing a 1,2,3-triazole ring (Scheme 4). 
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2.1.3. Starting from 10-Aminovindoline (5) with Chloroacethyl Chloride
10-Aminovindoline (5) was N-acylated with chloroacethyl chloride,
giving 10-chloroacethamido-vindoline (13, 63%), which was then coupled with (l)- and (d)-tryptophan
methylester to afford the expected conjugated derivatives (14, 15) in yields of 22% and 21%, respectively
(Scheme 3).
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2.2. Preparation of Vindoline Derivatives Coupled to a 1,2,3-Triazole Moiety
2.2.1. Click Reaction Using Linker between the Two Pharmacophores
The first step was the preparation of the 4-oxo-4-(prop-2-ynyl xy)butanoic acid (16) known in the
literature [32]. This compound (16) c uld be connected to 17-desacetylvindoline (9) in the presence of
N,N’-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) in ichloromethane
(DCM), aff rding compound 17 in 34% yiel . Compound 17 was coupled with 4-fluorobenzyl-azide
(18) [17] utilizing the widely k own copper-catalyzed click che istry [16]. The reaction was
performed in the presence of triphenylphosphine, copper(I) iodide and N,N-diisopropylethylamine
(DIPEA) in toluene under reflux to provid the expected conjugated pr duct (19) in a yield of 24%,
containing a 1,2,3-triazole ring (Scheme 4).
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Scheme 4. The click reaction of compound 17 and 4-fluorobenzyl-azide (18). 
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had to be synthesized first from propargyl-bromide in the presence of hexamethylphosphoramide 
and n-buthyllithium in tetrahydrofuran initially at 0 °C, and then by stirring at room temperature. 
After the click reaction of 17-propargylvindoline (20) and 4-fluorobenzyl-azide (18) the expected 
product (21) was successfully obtained in a yield of 46% (Scheme 5). 
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As a start, 17-desacetylvindoline (9) was O-acylated with 4-bromobutyric acid, resulting in the 
formation of the expected 17-(4-bromobutanoyloxy)vindoline (22) [22,23]. After this, linker-
containing 17-desacetylvindoline derivative (22) had been synthesized, the next step was to couple it 
with the chosen synthetic pharmacophores (morpholine, piperazine and N-methylpiperazine). 
First, the coupling reaction with morpholine was studied (Scheme 6). Compound 22 and 
morpholine was refluxed for 11 h in DCM to afford the expected product (23) in a yield of 74%. Using 
piperazine in DCM provided a dimer product (24, 36%) after refluxing for 7 h. (Scheme 6). The 
preparation of a functionalized derivative only on one side of piperazine (25, 43%) was accomplished 
using N-methylpiperazine in DCM after refluxing for 12 h (Scheme 6). 
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I this reaction, the pharmacophore 1,2,3-triazole deri ative was connected to
17-desacetylvindoline (9) through only a methylene group. In this case, 17-propargylvindoline (20, 32 )
a to be synthesized first from propargyl-bromide in the presence of hexamethylphosphoramide and
n-buthyllithium in tetrahydrofuran initially at 0 ◦C, and then by stirring at room temperature. After the
click reaction of 17-propargylvindoline (20) and 4-fluorobenzyl-azide (18) the expected product (21)
was successfully obtained in a yield of 46% (Scheme 5).
Scheme 5. The click reaction of 17-propargylvindoline (20) and 4-fluorobenzyl-azide (18).
2.3. Preparation of Vindoline Derivatives Coupled to Morpholine, Piperazine and N-Methylpiperazine Starting
from 17-Desacetylvindoline (9)
As a start, 17-desacetylvindoline (9) was O-acylated with 4-bromobutyric acid, resulting in the
formation of the expected 17-(4-bromobutanoyloxy)vindoline (22) [22,23]. After this, linker-containing
17-desacetylvindoline derivative (22) had been synthesized, the next step was to couple it with the
chosen synthetic pharmacophores (morpholine, piperazine and N-methylpiperazine).
First, the coupling reaction with morpholine was studied (Scheme 6). Compound 22 and
morpholine was refluxed for 11 h in DCM to afford the expected product (23) in a yield of 74%.
Using piperazine in DCM provided a dimer product (24, 36%) after refluxing for 7 h. (Scheme 6).
The preparation of a functionalized derivative only on one side of piperazine (25, 43%) was accomplished
using N-methylpiperazine in DCM after refluxing for 12 h (Scheme 6).
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Scheme 6. N-alkylation of morpholine, piperazine and N-methylpiperazine with 17-(4-
bromobutanoyloxy)vindoline (23). 
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The compounds were tested for their antiproliferative activity on a set of human gynecological 
cancer cell lines, such as HeLa and SiHa (cervical), and MCF-7 and MDA-MB-231 (breast); the results 
are presented in Table 1. 
Table 1. In vitro antiproliferative activity of selected compounds against human gynecological cancer 
cell lines. Compounds were tested in the concentration range of 0.1–30 µM in 2 biological replicates, 
5 parallel measurements each. IC50 values and their 95% confidence intervals (C.I.) are presented. Bold 
font of numbers mean stronger IC50 values compared to vinblastine (3) sulfate on SiHa cells. 
IC50 [95% C.I.] (µM) 
COMPOUND HeLa SiHa MCF-7 MDA-MB-231 
vindoline (1) >30 >30 >30 >30 
vinblastine (3) sulfate <0.1 14.42  
[12.75–16.31] <0.1 <0.1 
17-desacetylvindoline (9) >30 >30 >30 >30 
7 >30 >30 >30 >30 
8 >30 >30 >30 >30 
11 >30 6.01  
[5.45–6.62] 
>30 
8.59  
[7.63–9.68] 
12 12.03  
[9.76–14.84] 
12.29  
[10.29–14.68] 
13.09  
[10.93–15.68] 
~20.41 a 
14 >30 >30 >30 >30 
15 >30 >30 >30 >30 
19 >30 >30 >30 >30 
21 >30 >30 >30 >30 
23 >30 >30 >30 >30 
24 3.21  
[2.68–3.84] 
2.85  
[2.42–3.36] 
3.63  
[2.93–4.51] 
3.52  
[1.75–7.10] 
25 9.36  
[8.87–9.87] 
>30 
14.10  
[11.36–17.50] 
25.49  
[22.32–29.11] 
a Ambiguous fitting, no confidence interval available. 
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2.4. Biology
The compounds were tested for their antiproliferative activity on a set of human gynecological
cancer cell lines, such as HeLa and SiHa (cervical), and MCF-7 and MDA-MB-231 (breast); the results
are presented in Table 1.
As expected, vindoline (1) and 17-desacetylvindoline (9) exhibited only inconsiderable anticancer
activity on the studied cancer cell lines, while vinblastine (3) sulfate showed potent antitumor action
with IC50 values bel w 100 nM on most c ll lin s except for SiHa that was much more resistant to this
chemotherapeutic agent (IC50 = 14.42 µM). How ver, a few of th tested Vinca derivatives (11, 12 and
24) sh wed promi ing re ults, and this was particularly true concerning their activity on SiHa cells
on which vinblastine (3) sulfate was the weakest. Compound 12 proved to be more effective than
vindoline (1) on all cell lines and had an IC50 value (12.29 µM) very similar to that of vinblastine (3)
sulfate (14.42 µM) on SiHa cells. Compound 24 had not only lower IC50 values than vindoline (1)
but proved to be 5-times more effective than vinblastine (3) sulfate against SiHa cells. Compound 11
also had a lower IC50 value (6.01 µM) than vinblastine (3) sulfate on SiHa cells. Of the tested new
compounds (not counting references), 24 gave the lowest IC50 value (2.85 µM on SiHa cells), and more
interestingly, compounds 11, 12, and 24 were all more potent than vinblastine (3) sulfate on SiHa cells.
Accordingly, these compounds demonstrated a dramatic difference compared to vinblastine (3) sulfate
in their cell line selectivity on HeLa and SiHa cells. While SiHa cells were over 144 times more resistant
to vinblastine (3) sulfate than HeLa cells, this relative resistance disappeared in the case of compounds
12 and 24, and even turned to the opposite direction in the case of compound 11 that was at least
5 times more potent against SiHa than HeLa cells. This suggests different biochemical target(s) for
these compounds as compared to vinblastine (3).
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Table 1. In vitro antiproliferative activity of selected compounds against human gynecological cancer
cell lines. Compounds were tested in the concentration range of 0.1–30 µM in 2 biological replicates,
5 parallel measurements each. IC50 values and their 95% confidence intervals (C.I.) are presented.
Bold font of numbers mean stronger IC50 values compared to vinblastine (3) sulfate on SiHa cells.
IC50 [95% C.I.] (µM)
COMPOUND HeLa SiHa MCF-7 MDA-MB-231
vindoline (1) >30 >30 >30 >30
vinblastine (3) sulfate <0.1 14.42 [12.75–16.31] <0.1 <0.1
17-desacetylvindoline (9) >30 >30 >30 >30
7 >30 >30 >30 >30
8 >30 >30 >30 >30
11 >30 6.01 [5.45–6.62] >30 8.59 [7.63–9.68]
12 12.03 [9.76–14.84] 12.29 [10.29–14.68] 13.09 [10.93–15.68] ~20.41 a
14 >30 >30 >30 >30
15 >30 >30 >30 >30
19 >30 >30 >30 >30
21 >30 >30 >30 >30
23 >30 >30 >30 >30
24 3.21 [2.68–3.84] 2.85 [2.42–3.36] 3.63 [2.93–4.51] 3.52 [1.75–7.10]
25 9.36 [8.87–9.87] >30 14.10 [11.36–17.50] 25.49 [22.32–29.11]
a Ambiguous fitting, no confidence interval available.
Concerning structure–activity relationships, it seems that the 1,2,3-triazole and morpholine
moieties could not improve the efficacy of vindoline (1) at all.
To summarize, vindoline (1) conjugated with amino acids [(l)- and (d)-tryptophan methyl ester]
(compounds 11 and 12, respectively), piperazine and N-methylpiperazine (compounds 24 and 25,
respectively) had significant antiproliferative effect, even though the monomer vindoline (1) itself
was inactive.
3. Experimental Section
3.1. General
All the reagents were purchased from Sigma-Aldrich (Budapest, Hungary) and used as received.
Melting points were measured on a VEB Analytik Dresden PHMK-77/1328 apparatus (Dresden,
Germany) and are uncorrected. IR spectra were recorded on Zeiss IR 75 and 80 instruments (Thornwood,
NY, USA). NMR measurements were performed on a Bruker Avance III HDX 400 MHz NMR
spectrometer equipped with a 15N-31P{1H-19F} 5 mm CryoProbe Prodigy (31P: 161.8 MHz), a Bruker
Avance III HDX 500 MHz NMR spectrometer equipped with a 1H{13C/15N} 5 mm TCI CryoProbe (1H:
499.9 MHz, 13C: 125.7 MHz), and a Bruker Avance III HDX 800 MHz NMR spectrometer equipped with
a 1H-19F{13C/15N} 5 mm TCI CryoProbe (1H: 799.7 MHz, 13C: 201.1 MHz) (Bruker Corporation, Billerica,
MA, USA). 1H-1H, direct 1H-13C, and long-range 1H-13C scalar spin-spin connectivity were established
from two-dimensional 1H-1H correlation spectroscopy (2D COSY), HSQC, and1H-13C heteronuclear
single quantum coherence (HMBC) experiments. 1H-1H spatial proximities were determined using
two-dimensional 1H-1H nuclear Overhauser effect spectroscopy (NOESY) or 1H-1H rotating frame
nuclear Overhauser effect spectroscopy (ROESY) experiments. 1H and 13C chemical shifts are given on
the delta scale relative to tetramethylsilane. 15N chemical shifts were determined on the basis of the
1H-15N HMBC data and are given on the delta scale relative to nitromethane. All pulse sequences were
applied by using the standard spectrometer software package. All experiments were performed at
298 K. NMR spectra were processed using Bruker TopSpin 3.5 pl 7 (Bruker Corporation, Billerica, MA,
USA) and ACD/Spectrus Processor version 2017.2.2 (Advanced Chemistry Development, Inc., Toronto,
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ON, Canada). ESI-HRMS and MS-MS analyses were performed on a Thermo Velos Pro Orbitrap Elite
(Thermo Fisher Scientific, Bremen, Germany) system. The ionization method was ESI, operated in
positive ion mode. The protonated molecular ion peaks were fragmented by CID (collision-induced
dissociation) at a normalized collision energy of 35–45%. For the CID experiment helium was
used as the collision gas. The samples were dissolved in methanol. Data acquisition and analysis
were accomplished with Xcalibur software version 2.0 (Thermo Fisher Scientific, Bremen, Germany).
EI-HRMS analyses were performed on a Thermo Q Exactive GC Orbitrap system. The ionization
method was EI and was operated in positive ion mode. The electron energy was 70 eV and the source
temperature was set to 250 ◦C. Data acquisition and analysis were accomplished with Xcalibur software
version 4.0 (Thermo Fisher Scientific, Bremen, Germany). TLC was carried out using DC-Alufolien
Kieselgel 60 F254 (Merck, Budapest, Hungary) plates. Preparative TLC analyses were performed on
silica gel 60 PF254+366 (Merck, Budapest, Hungary) glass plates. 1H and 13C NMR data of all the new
compounds are available online as a Supplementary Materials.
3.2. Synthesis of 10-(3-Carboxypropanamido)vindoline (6)
10-Aminovindoline (5) [30] (450 mg, 0.95 mmol) and succinic anhydride (144 mg, 1.4 mmol) were
dissolved in 20 mL of dry toluene. MS 4 Å molecular sieve was added to the mixture under argon.
The reaction mixture was heated to 80 ◦C and worked up after 32 h. The molecular sieve was filtered
and the precipitate remaining on the filter was washed with EtOH. The mixture was evaporated
under reduced pressure, then 20 mL of distilled water was added, and the pH was adjusted to 7
with ammonia solution. The aqueous phase was extracted with chloroform (4 × 40 mL). The organic
phase was dried over MgSO4, then the solvent evaporated under reduced pressure. After preparative
TLC (chloroform-methanol = 10:1) 342 mg (63%) of a yellow solid (6) was obtained. Mp 147–149 ◦C.
TLC (chloroform-methanol = 10:1); Rf = 0.43. IR (KBr): 3425, 2964, 1742, 1527, 1245, 1039 cm−1.
1H NMR (399.8 MHz; DMSO-d6) δ (ppm) 0.43 (t; J = 7.3 Hz; 3H; H3-18); 0.95 (dq; J = 13.9; 7.3 Hz;
1H; Hx-19); 1.47 (dq; J = 13.9; 7.3 Hz; 1H; Hy-19); 1.94 (s; 3H; C(17)-OC(O)CH3); 2.17–2.25 (m; 2H;
H2-6); 2.41–2.48 (br m; 2H; H2-3′); 2.50–2.57 (m; 3H; Hx-5. H2-2′); 2.58 (s; 3H; N(1)-CH3); 2.59 (s; 1H;
H-21); 2.78–2.86 (m; 1H; Hx-3); 3.24–3.32 (m; 1H; Hy-5); 3.37–3.44 (m; 1H; Hy-3); 3.51 (s; 1H; H-2); 3.66
(s; 3H; C(16)-COOCH3); 3.80 (s; 3H; C(11)-OCH3); 5.06–5.10 (m; 1H; H-15); 5.21 (s; 1H; H-17); 5.82 (ddd;
J = 10.1; 4.8; 1.1 Hz; 1H; H-14); 6.39 (s; 1H; H-12); 7.57 (s; 1H; H-9); 8.80 (br; 1H; C(16)-OH); 8.92 (s; 1H;
C(10)-NH).
13C NMR (100.5 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 20.6 (C(17)-OC(O)CH3); 29.1 (C-3′); 30.4
(C-19); 30.7 (C-2′); 38.7 (N(1)-CH3); 42.4 (C-20); 43.6 (C-6); 50.3 (C-3); 51.2 (C-5); 51.6 (C(16)-COOCH3);
52.3 (C-7); 55.6 (C(11)-OCH3); 66.2 (C-21); 75.8 (C-17); 78.6 (C-16); 82.9 (C-2); 93.9 (C-12); 117.5 (C-9);
119.3 (C-10); 123.5 (C-8); 124.4 (C-14); 129.8 (C-15); 149.2 (C-13); 151.1 (C-11); 169.6 (C-1′); 170.0
(C(17)-OC(O)CH3); 171.6 (C(16)-COOCH3); 173.9 (br; C-4′).
ESI-HRMS: M + H = 572.26097 (delta = 1.3 ppm; C29H38O9N3). HR-ESI-MS-MS (CID = 35%; rel.
int. %): 554(12); 512(100); 494(3); 480(2); 303(9).
3.3. Amidation of 10-(3-Carboxypropanamido)vindoline (6) and (l)-Tryptophan Methyl Ester
77 mg (0.35 mmol) of (l)-tryptophan methyl ester was liberated from its hydrochloric acid salt,
and dissolved in 10 mL of anhydrous DCM. Under argon at 0 ◦C, 200 mg (0.35 mmol) of compound 6
was added. Then, 110 mg (0.53 mmol) of DCC was dissolved in 6 mL of anhydrous DCM and added
dropwise into the reaction mixture. Subsequently, the mixture was allowed to reach room temperature.
After 19 h, the reaction mixture was filtered, and the filtrate was evaporated under reduced pressure.
After preparative TLC (dichloromethane-methanol = 10:1) 169 mg (63%) of a pale yellow solid (7) was
obtained. Mp 140–141 ◦C. TLC (dichloromethane-methanol = 10:1); Rf = 0.35. IR (KBr): 3370, 2952,
1742, 1525, 1245, 1039, 743 cm−1.
1H NMR (799.7 MHz; DMSO-d6) δ (ppm) 0.42 (t; J = 7.3 Hz; 3H; H3-18); 0.94 (dq; J = 14.1; 7.3 Hz;
1H; Hx-19); 1.47 (dq; J = 14.1; 7.3 Hz; 1H; Hy-19); 1.94 (s; 3H; C(17)-OC(O)CH3); 2.17–2.23 (m; 2H; H2-6);
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2.35–2.44 (m; 2H; H2-6′’); 2.47–2.53 (m; 3H; H2-7′’; Hx-5); 2.58 (~s; 4H; N(1)-CH3; H-21); 2.75–2.79 (m;
1H; Hx-3); 3.03 (dd; J = 14.5; 8.1 Hz; 1H; Hx-1′’); 3.11 (dd; J = 14.5; 6.0 Hz; 1H; Hy-1′’); 3.25–3.28 (m; 1H;
Hy-5); 3.37–3.41 (m; 1H; Hy-3); 3.50 (s; 1H; H-2); 3.55 (s; 3H; C(3′’)-OCH3); 3.65 (s; 3H; C(16)-COOCH3);
3.78 (s; 3H; C(11)-OCH3); 4.47–4.51 (m; 1H; H-2′’); 5.06–5.09 (m; 1H; H-15); 5.20 (s; 1H; H-17); 5.81 (ddd;
J = 10.1; 4.9; 1.1 Hz; 1H; H-14); 6.38 (s; 1H; H-12); 6.97–7.00 (m; 1H; H-5′); 7.05–7.08 (m; 1H; H-6′); 7.16
(d; J = 1.6 Hz; 1H; H-2′); 7.33 (d; J = 8.1 Hz; 1H; H-7′); 7.48 (d; J = 7.8 Hz; 1H; H-4′); 7.53 (s; 1H; H-9);
8.33 (d; J = 7.5 Hz; 1H; NH-4′’); 8.78 (s; 1H; C(16)-OH); 8.89 (s; 1H; NH-9′’); 10.85–10.87 (m; 1H; NH-1′).
13C NMR (201.1 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 20.6 (C(17)-OC(O)CH3); 27.1 (C-1′’); 30.2
(C-6′’); 30.4 (C-19); 31.0 (C-7′’); 38.7 (N(1)-CH3); 42.4 (C-20); 43.6 (C-6); 50.3 (C-3); 51.1 (C-5); 51.6
(C(16)-COOCH3; C(3′’)-OCH3); 52.3 (C-7); 53.1 (C-2′’); 55.6 (C(11)-OCH3); 66.2 (C-21); 75.8 (C-17); 78.6
(C-16); 82.9 (C-2); 93.9 (C-12); 109.3 (C-3′); 111.3 (C-7′); 117.8 (C-9); 117.9 (C-4′); 118.3 (C-5′); 119.1
(C-10); 120.8 (C-6′); 123.4 (C-8); 123.6 (C-2′); 124.3 (C-14); 126.9 (C-3a’); 129.8 (C-15); 135.9 (C-7a’); 149.3
(C-13); 151.3 (C-11); 169.8 (C-8′’); 169.9 (C(17)-OC(O)CH3); 171.4 (C-5′’); 171.5 (C(16)-COOCH3); 172.3
(C-3′’).
ESI-HRMS: M + H = 772.35419 (delta = −1.3 ppm; C41H50O10N5). HR-ESI-MS-MS (CID=35%; rel.
int. %): 754(13); 712(100); 694(3); 680(3); 610(2); 554(3); 503(11); 494(3); 472(3); 443(4); 412(4).
3.4. Amidation of 10-(3-Carboxypropanamido)vindoline (6) and (d)-Tryptophan Methyl Ester
39 mg (0.18 mmol) of (d)-tryptophan methyl ester was liberated from its hydrochloric acid salt,
and dissolved in 5 mL of anhydrous DCM. Under argon at 0 ◦C, 100 mg (0.18 mmol) of compound 6
was added. Then, 55 mg (0.26 mmol) of N,N’-dicyclohexylcarbodiimide (DCC) was dissolved in 3 mL
of anhydrous DCM and added dropwise into the reaction mixture. Subsequently, the mixture was
allowed to reach room temperature. After 8 h, the reaction mixture was filtered, and the filtrate was
evaporated under reduced pressure. After preparative TLC (dichloromethane-methanol = 10:1) 36 mg
(27%) of a pale yellow solid (8) was obtained. Mp 152–153 ◦C. TLC (dichloromethane-methanol = 10:1);
Rf = 0.41. IR (KBr): 3308, 2952, 1742, 1525, 1225, 1039, 743 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.42 (t; J = 7.3 Hz; 3H; H3-18); 0.95 (dq; J = 14.2; 7.3 Hz;
1H; Hx-19); 1.46 (dq; J = 14.2; 7.3 Hz; 1H; Hy-19); 1.93 (s; 3H; C(17)-OC(O)CH3); 2.15–2.24 (m; 2H;
H2-6); 2.37–2.43 (m; 2H; H2-6′’); 2.46–2.54 (m; 3H; H2-7′’; Hx-5); 2.58 (br s; 1H; H-21. s; 3H; N(1)-CH3);
2.74–2.79 (m; 1H; Hx-3); 3.00–3.06 (m; 1H; Hx-1′’); 3.10–3.15 (m; 1H; Hy-1′’); 3.24–3.29 (m; 1H; Hy-5);
3.35–3.42 (m; 1H; Hy-3); 3.51 (s; 1H; H-2); 3.55 (s; 3H; C(3′’)-OCH3); 3.65 (s; 3H; C(16)-COOCH3);
3.78 (s; 3H; C(11)-OCH3); 4.47–4.53 (m; 1H; H-2′’); 5.05–5.09 (m; 1H; H-15); 5.20 (s; 1H; H-17); 5.81
(ddd; J = 10.1; 4.9; 1.5 Hz; 1H; H-14); 6.38 (s; 1H; H-12); 6.96–7.00 (m; 1H; H-5′); 7.04–7.08 (m; 1H; H-6′);
7.16 (d; J = 2.2 Hz; 1H; H-2′); 7.31–7.35 (m; 1H; H-7′); 7.46–7.50 (m; 1H; H-4′); 7.54 (s; 1H; H-9); 8.32 (d; J
= 7.5 Hz; 1H; NH-4′’); 8.78 (br s; 1H; C(16)-OH); 8.88 (s; 1H; NH-9′’); 10.86 (br d; J = 2.2 Hz; 1H; NH-1′).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 20.6 (C(17)-OC(O)CH3); 27.1 (C-1′’); 30.2
(C-6′’); 30.4 (C-19); 31.1 (C-7′’); 38.7 (N(1)-CH3); 42.4 (C-20); 43.6 (C-6); 50.3 (C-3); 51.1 (C-5); 51.6
(C(3′’)-OCH3. C(16)-COOCH3); 52.3 (C-7); 53.1 (C-2′’); 55.6 (C(11)-OCH3); 66.2 (C-21); 75.8 (C-17); 78.6
(C-16); 82.9 (C-2); 93.9 (C-12); 109.3 (C-3′); 111.3 (C-7′); 117.8 (C-9); 117.9 (C-4′); 118.3 (C-5′); 119.2
(C-10); 120.8 (C-6′); 123.5 (C-8); 123.6 (C-2′); 124.4 (C-14); 127.0 (C-3a’); 129.8 (C-15); 136.0 (C-7a’); 149.3
(C-13); 151.3 (C-11); 169.8 (C-8′’); 170.0 (C(17)-OC(O)CH3); 171.4 (C-5′’); 171.5 (C(16)-COOCH3); 172.3
(C-3′’).
ESI-HRMS: M + H = 772.35387 (delta = −1.75 ppm; C41H50O10N5). HR-ESI-MS-MS (CID=35%;
rel. int. %): 754(15); 712(100); 694(3); 680(3); 610(2); 554(3); 503(13); 494(4); 472(4); 443(6); 412(5).
3.5. Amidation of 17-(3-Carboxypropanoyloxy)vindoline (10) and (l)-Tryptophan Methyl Ester
85 mg (0.39 mmol) of (l)-tryptophan methyl ester was liberated from its hydrochloric acid salt, and
dissolved in 10 mL of anhydrous DCM. Under argon the mixture was cooled to 0 ◦C, and 200 mg (0,39
mmol) of compound 10 [31] was added. Then, 82 mg (0.39 mmol) of DCC dissolved in 5 mL anhydrous
DCM was added dropwise into the reaction mixture. Then, the mixture was allowed to reach room
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temperature. After stirring for 22 h, the precipitate was filtered, and the filtrate was evaporated under
reduced pressure. After preparative TLC (dichloromethane-methanol = 10:1) 170 mg (61%) of a pale
yellow solid (11) was obtained. Mp 131–133 ◦C. TLC (dichloromethane-methanol = 20:1); Rf = 0.34. IR
(KBr): 3369, 2952, 1741, 1502, 1225, 1168, 1027, 744 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.41 (t; J = 7.3 Hz; 3H; H3-18); 0.92 (dq; J = 14.1; 7.3 Hz;
1H; Hx-19); 1.46 (dq; J = 14.1; 7.3 Hz; 1H; Hy-19); 2.14–2.24 (m. 2H; H2-6); 2.27–2.45 (m; 4H; H2-6′’.
H2-7′’); 2.52–2.59 (m; 1H; Hx-5); 2.56 (s; 3H; N(1)-CH3); 2.65 (s; 1H; H-21); 2.74–2.80 (m; 1H; Hx-3);
2.99–3.06 (m; 1H; Hx-1′’); 3.10–3.15 (m; 1H; Hy-1′’); 3.24–3.30 (m; 1H; Hy-5); 3.35–3.41 (m; 1H; Hy-3);
3.54 (~s; 4H; H-2. C(3′’)-OCH3); 3.63 (s; 3H; C(16)-COOCH3); 3.70 (s; 3H; C(11)-OCH3); 4.45–4.50 (m;
1H; H-2′’); 5.11–5.15 (m; 1H; H-15); 5.18 (s; 1H; H-17); 5.75 (ddd; J = 10.2; 4.8; 1.3 Hz; 1H; H-14); 6.19 (d;
J = 2.2 Hz; 1H; H-12); 6.28 (dd; J = 8.2; 2.2 Hz; 1H; H-10); 6.96–7.00 (m; 1H; H-5′); 7.04 (d; J = 8.2 Hz;
1H; H-9); 7.04–7.08 (m; 1H; H-6′); 7.14 (d; J = 2.3 Hz; 1H; H-2′); 7.32–7.35 (m; 1H; H-7′); 7.46–7.49 (m;
1H; H-4′); 8.36 (d; J = 7.5 Hz; 1H; NH-4′’); 8.80 (br s; 1H; C(16)-OH); 10.86 (br d; J = 2.3 Hz; 1H; NH-1′).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 27.0 (C-1′’); 28.9. 29.6 (C-6′’. C-7′’); 30.3 (C-19);
38.0 (N(1)-CH3); 42.4 (C-20); 43.7 (C-6); 50.3 (C-3); 51.0 (C-5); 51.6 (C(3′’)-OCH3); 51.7 (C(16)-COOCH3);
52.0 (C-7); 53.2 (C-2′’); 55.0 (C(11)-OCH3); 66.0 (C-21); 75.8 (C-17); 78.6 (C-16); 82.8 (C-2); 95.4 (C-12);
104.4 (C-10); 109.3 (C-3′); 111.3 (C-7′); 117.9 (C-4′); 118.3 (C-5′); 120.9 (C-6′); 123.0 (C-9); 123.6 (C-2′);
124.1 (C-14); 125.3 (C-8); 127.0 (C-3a’); 129.9 (C-15); 136.0 (C-7a’); 153.4 (C-13); 160.4 (C-11); 170.7 (C-5′’);
171.5 (C(16)-COOCH3); 171.8 (C-8′’); 172.3 (C-3′’).
15N NMR (50.7 MHz; DMSO-d6) δ (ppm) −323.2 (N-4); -315.0 (N-1); −262.2 (N-4′’); −250.8 (N-1′).
ESI-HRMS: M + H = 715.33393 (delta = 0.24 ppm; C39H47O9N4). HR-ESI-MS-MS (CID = 35%; rel.
int. %): 697(100); 415(6); 397(9).
3.6. Amidation of 17-(3-Carboxypropanoyloxy)vindoline (10) and (d)-Tryptophan Methyl Ester
85 mg (0.39 mmol) of (d)-tryptophan methyl ester was liberated from its hydrochloric acid salt,
and dissolved in 10 mL of anhydrous DCM. Under argon the mixture was cooled to 0 ◦C, and 200 mg
(0,39 mmol) of compound 10 [31] was added. Then, 82 mg (0.39 mmol) of DCC dissolved in 5 mL
of anhydrous DCM was added dropwise into the reaction mixture. Then, the mixture was allowed
to reach room temperature. After stirring for 22 h, the precipitate was filtered, and the filtrate was
evaporated under reduced pressure. After preparative TLC (dichloromethane-methanol = 15:1) 133
mg (48%) of a pale yellow solid (12) was obtained. Mp 141–143 ◦C. TLC (dichloromethane-methanol =
15:1); Rf = 0.54. IR (KBr): 3380, 2952, 1741, 1502, 1225, 1168, 1028, 744 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.40 (t; J = 7.4 Hz; 3H; H3-18); 0.92 (dq; J = 14.3; 7.4 Hz;
1H; Hx-19); 1.46 (dq; J = 14.3; 7.4 Hz; 1H; Hy-19); 2.14–2.24 (m. 2H; H2-6); 2.27–2.45 (m; 4H; H2-6′’.
H2-7′’); 2.52–2.59 (m; 1H; Hx-5); 2.56 (s; 3H; N(1)-CH3); 2.65 (s; 1H; H-21); 2.75–2.82 (m; 1H; Hx-3);
2.98–3.05 (m; 1H; Hx-1′’); 3.08–3.14 (m; 1H; Hy-1′’); 3.24–3.30 (m; 1H; Hy-5); 3.38–3.44 (m; 1H; Hy-3);
3.54 (s; 1H; H-2); 3.55 (s; 3H; C(3′’)-OCH3); 3.63 (s; 3H; C(16)-COOCH3); 3.70 (s; 3H; C(11)-OCH3);
4.46–4.52 (m; 1H; H-2′’); 5.12–5.16 (m; 1H; H-15); 5.19 (s; 1H; H-17); 5.81 (ddd; J = 10.3; 4.8; 1.3 Hz;
1H; H-14); 6.18 (d; J = 2.3 Hz; 1H; H-12); 6.28 (dd; J = 8.2; 2.3 Hz; 1H; H-10); 6.94–6.98 (m; 1H; H-5′);
7.03–7.07 (m; 1H; H-6′); 7.04 (d; J = 8.2 Hz; 1H; H-9); 7.13 (d; J = 2.3 Hz; 1H; H-2′); 7.31–7.34 (m; 1H;
H-7′); 7.46–7.48 (m; 1H; H-4′); 8.35 (d; J = 7.5 Hz; 1H; NH-4′’); 8.79 (br s; 1H; C(16)-OH); 10.85 (br d;
J = 2.3 Hz; 1H; NH-1′).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 27.0 (C-1′’); 28.9. 29.6 (C-6′’. C-7′’); 30.3 (C-19);
38.0 (N(1)-CH3); 42.4 (C-20); 43.7 (C-6); 50.3 (C-3); 51.0 (C-5); 51.6 (C(3′’)-OCH3); 51.7 (C(16)-COOCH3);
52.0 (C-7); 53.1 (C-2′’); 55.0 (C(11)-OCH3); 66.1 (C-21); 75.8 (C-17); 78.6 (C-16); 82.8 (C-2); 95.4 (C-12);
104.4 (C-10); 109.3 (C-3′); 111.3 (C-7′); 117.9 (C-4′); 118.3 (C-5′); 120.8 (C-6′); 123.0 (C-9); 123.5 (C-2′);
124.1 (C-14); 125.3 (C-8); 127.0 (C-3a’); 130.0 (C-15); 136.0 (C-7a’); 153.4 (C-13); 160.4 (C-11); 170.7 (C-5′’);
171.6 (C(16)-COOCH3); 171.8 (C-8′’); 172.3 (C-3′’).
ESI-HRMS: M + H = 715.33370 (delta = −0.08 ppm; C39H47O9N4). HR-ESI-MS-MS (CID = 45%;
rel. int. %): 697(100); 415(5); 397(9).
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3.7. N-Acylation of 10-Aminovindoline (5) with Chloroacetyl Chloride
978 mg (2.1 mmol) of 10-aminovindoline (5) [30] was dissolved in 20 mL of anhydrous DCM under
argon, then 321 mg (2.3 mmol) of anhydrous K2CO3 was added. The reaction mixture was cooled to
0 ◦C, and 1.71 mL (21.5 mmol) of chloroacetyl chloride was added dropwise. The mixture was allowed
to reach room temperature. After stirring for 6 h, the reaction mixture was filtered, and the filtrate
was washed with 50 mL of 10% NaHCO3 solution. The aqueous phase was extracted with 2 × 50 mL
DCM. The organic phase was dried over MgSO4, then the solvent evaporated under reduced pressure.
After preparative TLC (ethyl acetate: methanol = 15:1) 712 mg (63%) of a white crystalline pure product
(13) was obtained. Mp 168 ◦C. TLC (ethyl acetate: methanol = 20:1); Rf = 0.30. IR (KBr): 3392, 2964,
1743,1533, 1245, 1039 cm−1.
1H NMR (499.9 MHz; CDCl3) δ (ppm) 0.53 (3H; t; J = 7.3 Hz; H3-18); 1.08 (1H; dq; J = 14.3; 7.3 Hz;
Hx-19); 1.62 (1H; dq; J = 14.3; 7.3 Hz; Hy-19); 2.08 (3H; s; C(17)-OC(O)CH3); 2.25–2.40 (2H; m; H2-6);
2.54–2.63 (1H; m; Hx-5); 2.69 (3H; s; N(1)-CH3); 2.77 (1H; s; H-21); 2.81–2.89 (1H; m; Hx-3); 3.36–3.45
(1H; m; Hy-5); 3.45–3.54 (1H; m; Hy-3); 3.73 (1H; s; H-2); 3.79 (3H; s; C(16)-COOCH3); 3.91 (3H; s;
C(11)-OCH3); 4.16 (2H; ~s; C(10)-NH-C(O)CH2Cl); 5.24 (1H; br d; J = 10.4 Hz; H-15); 5.43 (1H; s; H-17);
5.86 (1H; ddd; J = 10.4; 5.0; 1.4 Hz; H-14); 6.13 (1H; s; H-12); 8.04 (1H; s; H-9); 8.72 (1H; br; C(10)-NH);
9.60 (1H; br; C(16)-OH).
13C NMR (201.1 MHz; CDCl3) δ (ppm) 7.6 (C-18); 21.1 (C(17)-OC(O)CH3); 31.0 (C-19); 38.9
(N(1)-CH3); 42.9 (C-20); 43.1 (C(10)-NH-C(O)CH2Cl); 43.9 (br; C-6); 50.9 (C-3); 51.5 (br; C-5); 52.3
(C(16)-COOCH3); 53.3 (br; C-7); 56.1 (C(11)-OCH3); 66.5 (br; C-21); 76.4 (C-17); 79.7 (C-16); 83.4 (br;
C-2); 93.2 (C-12); 114.5 (C-9); 119.0 (C-10); 123.6 (br; C-8); 124.2 (br; C-14); 130.4 (C-15); 149.5 (C-13);
149.9 (C-11); 163.0 (C(10)-NH-C(O)CH2Cl); 170.8 (C(17)-OC(O)CH3); 171.8 (C(16)-COOCH3).
ESI-HRMS: M + H = 548.21557 (delta = −0.4 ppm; C27H35O7N3Cl). HR-ESI-MS-MS (CID = 35%.
rel. int. %): 530(11); 488(100); 470(2);456(3); 428(2); 386(1); 279(7).
3.8. N-Alkylation of (l)-Tryptophan Methyl Ester with 10-Chloroacetamido-Vindoline (13)
10-Chloroacetamido-vindoline (13) (200 mg, 0.37 mmol) and (l)-tryptophan methyl ester (88 mg,
0.40 mmol; previously liberated from its hydrochloric acid salt) were dissolved in 5 mL of dry toluene
in a sealed glass. Then, 0.05 mL (0.37 mmol) of TEA was added. The sealed glass was placed in an oil
bath at 150 ◦C. After stirring for 15 h, the precipitate was filtered, and the filtrate was evaporated under
reduced pressure. After preparative TLC (dichloromethane-methanol = 10:1) 59 mg (22%) of a pale
green solid (14) was obtained. Mp 150–152 ◦C. TLC (dichloromethane-methanol = 10:1); Rf = 0.54.
IR (KBr): 3319, 2950, 1740, 1528, 1459, 1243, 1039, 743 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.42 (t; J = 7.3 Hz; 3H; H3-18); 0.96 (dq; J = 13.8; 7.3 Hz;
1H; Hx-19); 1.49 (dq; J = 13.8; 7.3 Hz; 1H; Hy-19); 1.95 (s; 3H; C(17)-OC(O)CH3); 2.17–2.28 (m; 2H; H2-6);
2.52–2.60 (m; 1H; Hx-5); 2.60 (s; 3H; N(1)-CH3); 2.65 (br s; 1H; H-21); 2.81–2.90 (m; 1H; Hx-3); 3.08–3.19
(m; 3H; H2-1′’. Hx-5′’); 3.31–3.41 (m; 2H; Hy-5. Hy-5′’); 3.41–3.48 (m; 1H; Hy-3); 3.53 (s; 1H; H-2); 3.55
(s; 3H; C(3′’)-OCH3); 3.58–3.62 (m; 1H; H-2′’); 3.66 (s; 3H; C(16)-COOCH3); 3.82 (s; 3H; C(11)-OCH3);
5.08–5.12 (m; 1H; H-15); 5.21 (s; 1H; H-17); 5.83 (ddd; J = 10.1; 4.8; 1.5 Hz; 1H; H-14); 6.45 (s; 1H; H-12);
6.93–6.97 (m; 1H; H-5′); 7.04–7.07 (m; 1H; H-6′); 7.14 (d; J = 2.2 Hz; 1H; H-2′); 7.32–7.35 (m; 1H; H-7′);
7.47–7.50 (m; 1H; H-4′); 7.91 (s; 1H; H-9); 8.79 (br s; 1H; C(16)-OH); 9.49 (s; 1H; NH-7′’); 10.89 (br d;
J = 2.2 Hz; 1H; NH-1′).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm): 7.4 (C-18). 20.6 (C(17)-OC(O)CH3). 28.5 (C-1′’). 30.4
(C-19). 38.8 (N(1)-CH3). 42.4 (C-20). 43.5 (C-6). 50.3 (C-3). 50.8 (C-5′’). 51.1 (C-5). 51.4 (C(3′’)-OCH3).
51.7 (C(16)-COOCH3). 52.4 (C-7). 55.9 (C(11)-OCH3). 61.7 (C-2′’). 66.2 (C-21). 75.7 (C-17). 78.6 (C-16).
82.6 (C-2). 94.0 (C-12). 109.2 (C-3′). 111.3 (C-7′). 114.5 (C-9). 117.9 (C-4′). 118.2 (C-5′). 119.3 (C-10).
120.8 (C-6′). 123.4 (C-8). 123.5 (C-2′). 124.3 (C-14). 127.1 (C-3a’). 129.8 (C-15). 136.0 (C-7a’). 148.7 (C-13).
149.8 (C-11). 168.3 (br; C-6′’). 170.0 (C(17)-OC(O)CH3). 171.5 (C(16)-COOCH3). 173.8 (br; C-3′’).
ESI-HRMS: M + H = 730.34419 (delta = −0.64 ppm; C39H48O9N5). HR-ESI-MS-MS (CID = 35%;
rel. int. %): 712(12); 670(100); 652(3); 568(4); 461(5); 433(3); 346(3).
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3.9. N-Alkylation of (d)-Tryptophan Methyl Ester with 10-Chloroacetamido-Vindoline (13)
10-Chloroacetamido-vindoline (13) (200 mg, 0.37 mmol) and (d)-tryptophan methyl ester (88 mg,
0.40 mmol; previously liberated from its hydrochloric acid salt) were dissolved in 5 mL of dry toluene
in a sealed glass. Then, 0.05 mL (0.37 mmol) of TEA was added. The sealed glass was placed in an oil
bath at 150 ◦C. After stirring for 12 h, the precipitate was filtered, and the filtrate was evaporated under
reduced pressure. After preparative TLC (dichloromethane-methanol = 10: 1) 56 mg (21%) of a pale
green solid (15) was obtained. Mp 157–159 ◦C. TLC (dichloromethane-methanol = 10:1); Rf = 0.58.
IR (KBr): 3325, 2950, 1740, 1528, 1459, 1244, 1039, 743 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.42 (t; J = 7.3 Hz; 3H; H3-18); 0.94 (dq; J =14.1; 7.3 Hz;
1H; Hx-19); 1.47 (dq; J =14.1; 7.3 Hz; 1H; Hy-19); 1.94 (s; 3H; C(17)-OC(O)CH3); 2.16–2.27 (m; 2H; H2-6);
2.50–2.56 (m; 1H; Hx-5); 2.60 (~s; 4H; N(1)-CH3. H-21); 2.79–2.85 (m; 1H; Hx-3); 2.92–3.11 (br m; 1H;
NH-4′’); 3.07–3.12 (m; 3H; Hx-5′’. H2-1′’); 3.28–3.38 (m; 2H; Hy-5. Hy-5′’); 3.39–3.45 (m; 1H; Hy-3);
3.52 (s; 1H; H-2); 3.55 (s; 3H; C(3′’)-OCH3); 3.55–3.60 (m; 1H; H-2′’); 3.66 (s; 3H; C(16)-COOCH3); 3.82
(s; 3H; C(11)-OCH3); 5.07–5.11 (m; 1H; H-15); 5.20 (s; 1H; H-17); 5.83 (ddd; J = 10.4; 4.2; 1.1 Hz; 1H;
H-14); 6.45 (s; 1H; H-12); 6.94–6.98 (m; 1H; H-5′); 7.03–7.07 (m; 1H; H-6′); 7.14 (d; J = 2.0 Hz; 1H; H-2′);
7.31–7.35 (m; 1H; H-7′); 7.47–7.51 (m; 1H; H-4′); 7.91 (s; 1H; H-9); 8.77 (br s; 1H; C(16)-OH); 9.48 (s; 1H;
NH-7′’); 10.88 (br d; J = 2.0 Hz; 1H; NH-1′).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 20.7 (C(17)-OC(O)CH3); 28.6 (C-1′’); 30.4
(C-19); 38.8 (N(1)-CH3); 42.4 (C-20); 43.6 (C-6); 50.4 (C-3); 51.0 (C-5′’); 51.1 (C-5); 51.4 (C(3′’)-OCH3);
51.6 (C(16)-COOCH3); 52.5 (C-7); 55.9 (C(11)-OCH3); 61.8 (C-2′’); 66.1 (C-21); 75.8 (C-17); 78.7 (C-16);
82.8 (C-2); 94.0 (C-12); 109.3 (C-3′); 111.3 (C-7′); 114.3 (C-9); 117.9 (C-4′); 118.3 (C-5′); 119.4 (C-10); 120.8
(C-6′); 123.4 (C-8); 123.5 (C-2′); 124.4 (C-14); 127.1 (C-3a’); 129.8 (C-15); 136.0 (C-7a’); 148.6 (C-13); 149.7
(C-11); 168.4 (C-6′’); 170.0 (C(17)-OC(O)CH3); 171.5 (C(16)-COOCH3); 174.0 (C-3′’).
ESI-HRMS: M+H=730.34353 (delta=-1.54 ppm; C39H48O9N5). HR-ESI-MS-MS (CID=35%; rel. int.
%): 712(13); 670(100); 652(3); 568(4); 461(7); 433(4); 346(4).
3.10. Synthesis of 17-[4-Oxo-4-(prop-2-ynyloxy)butanoyloxy]vindoline (17)
17-Desacetylvindoline (9) [31] (600 mg, 1.5 mmol) and 4-oxo-4- (prop-2-ynyloxy) butanoic acid
(16) (240 mg, 1.5 mmol) were dissolved in 15 mL of anhydrous DCM followed by a dropwise addition
of 330 mg (0.53 mmol) of DCC and 15 mg (0.039 mmol) of 4-dimethylaminopyridine (DMAP) dissolved
in another 15 mL of anhydrous DCM. The reaction mixture was refluxed for 4h, then further 250 mg
of DCC and 30 mg of DMAP dissolved in 20 mL of anhydrous DCM were added in two portions.
After refluxing for 46 h, the reaction mixture was filtered, and the filtrate was evaporated under
reduced pressure. After preparative TLC (dichloromethane: methanol = 10: 1) 269 mg (34%) of a pale
brown crystalline product (17) was obtained. Mp 123–130 ◦C. TLC (dichloromethane: methanol = 10:
1); Rf = 0.75. IR (KBr): 1156; 1223; 1262; 1619; 1732; 2944; 3258 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.42 (t; J = 7.4 Hz; 3H; H3-18); 0.94 (dq; J = 14.0. 7.4
Hz; 1H; Hx-19); 1.46 (dq; J = 14.0. 7.4 Hz; 1H; Hy-19); 2.17–2.25 (m; 2H; H2-6); 2.41–2.60 (m; 8H; H2-2′.
H2-3′. N(1)-CH3. Hx-5); 2.66 (s; 1H; H-21); 2.79 (ddd; J = 16.2. 2.7. 1.5 Hz; 1H; Hx-3); 3.25–3.31 (m; 1H;
Hy-5); 3.42 (ddd; J = 16.2. 4.9. 1.2 Hz; 1H; Hy-3); 3.54 (t; J = 2.5 Hz; 1H; H-7′); 3.55 (s; 1H; H-2); 3.65 (s;
3H; C(16)-COOCH3); 3.70 (s; 3H; C(11)-OCH3); 4.64–4.72 (m; 2H; H2-5′); 5.13 (ddd; J = 10.2. 2.7. 1.2
Hz; 1H; H-15); 5.20 (s; 1H; H-17); 5.83 (ddd; J = 10.2. 4.9. 1.5 Hz; 1H; H-14); 6.19 (d; J = 2.3 Hz; 1H;
H-12); 6.28 (dd; J = 8.2. 2.3 Hz; 1H; H-10); 7.05 (d; J = 8.2 Hz; 1H; H-9); 8.79 (s; 1H; C(16)-OH).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 28.3 (C-3′); 28.5 (C-2′); 30.3 (C-19); 38.0
(N(1)-CH3); 42.4 (C-20); 43.6 (C-6); 50.3 (C-3); 51.0 (C-5); 51.70 (C(16)-COOCH3); 51.73 (C-5′); 52.0 (C-7);
55.0 (C(11)-OCH3); 66.1 (C-21); 76.1 (C-17); 77.6 (C-7′); 78.2 (C-6′); 78.6 (C-16); 82.8 (C-2); 95.4 (C-12);
104.5 (C-10); 123.0 (C-9); 124.3 (C-14); 125.3 (C-8); 129.8 (C-15); 153.4 (C-13); 160.4 (C-11); 171.1 (C-4′);
171.3 (C-1′); 171.5 (C(16)-COOCH3).
15N NMR (50.7 MHz; DMSO-d6) δ (ppm) −322.4 (N-4); −314.2 (N-1).
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ESI-HRMS: M + H = 553.25395 (delta = −0.9ppm; C30H37O8N2). HR-ESI-MS-MS (CID = 35%; rel.
int. %): 535(11); 493(13); 397(100); 365(4); 188(25).
3.11. The Click Reaction of 17-[4-Oxo-4-(prop-2-ynyloxy)butanoyloxy]vindoline (17) and 4-Fluorobenzyl-Azide (18)
299 mg (0.54 mmol) of 17-[4-oxo-4-(prop-2-ynyloxy)butanoyloxy]vindoline (17), 86 mg (0.57 mmol)
of 4-fluorobenzyl-azide (18), 29 mg (0.11 mmol) of triphenylphosphine and 11 mg (0.054 mmol) of copper
(I) iodide were dissolved in 12 mL of dry toluene, then 0.29 mL (1.6 mmol) ofN,N-diisopropylethylamine
(DIPEA) was added, and the reaction mixture was refluxed for 4 h. Then, 75 mL of toluene was
added and the mixture was washed with 90 mL of distilled water, finally the aqueous phase was
washed with another 30 mL of toluene. The organic phase was dried over MgSO4, then the solvent
evaporated under reduced pressure. After preparative TLC (dichloromethane-methanol = 30:1 then
dichloromethane-methanol = 15:1) 90 mg (24%) of a white crystalline product (19) was obtained.
Mp 80–87 ◦C. TLC (dichloromethane-methanol = 15:1); Rf = 0,72. IR (KBr): 1158; 1225; 1503; 1738; 2838;
2962 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.41 (t; J = 7.4 Hz; 3H; H3-18); 0.93 (dq; J = 13.9. 7.4
Hz; 1H; Hx-19); 1.44 (dq; J = 13.9. 7.4 Hz; 1H; Hy-19); 2.17–2.25 (m; 2H; H2-6); 2.39–2.61 (m; 8H; H2-3′.
H2-2′. N(1)-CH3. Hx-5); 2.66 (s; 1H; H-21); 2.79 (br d; J = 16.1 Hz; 1H; Hx-3); 3.25–3.31 (m; 1H; Hy-5);
3.40 (br dd; J = 16.1. 4.9 Hz; 1H; Hy-3); 3.55 (s; 1H; H-2); 3.63 (s; 3H; C(16)-COOCH3); 3.70 (s; 3H;
C(11)-OCH3); 5.08–5.12 (m; 1H; H-15), 5.11 (s; 2H; H2-1′’); 5.20 (s; 1H; H-17); 5.58 (s; 2H; H2-7′’); 5.79
(ddd; J = 10.2. 4.9. 1.4 Hz; 1H; H-14); 6.19 (d; J = 2.2 Hz; 1H; H-12); 6.28 (dd; J = 8.2. 2.2 Hz; 1H; H-10);
7.05 (d; J = 8.2 Hz; 1H; H-9); 7.17–7.23 (m; 2H; H-10′’. H-12′’); 7.36–7.42 (m; 2H; H-9′’. H-13′’); 8.19 (s;
1H; H-6′’); 8.80 (s; 1H; C(16)-OH).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 28.4 (C-2′); 28.5 (C-3′); 30.4 (C-19); 38.0
(N(1)-CH3); 42.4 (C-20); 43.6 (C-6); 50.3 (C-3); 51.1 (C-5); 51.7 (C(16)-COOCH3); 51.9 (C-7′’); 52.0 (C-7);
55.0 (C(11)-OCH3); 57.3 (C-1′’); 66.1 (C-21); 76.1 (C-17); 78.6 (C-16); 82.7 (C-2); 95.4 (C-12); 104.5 (C-10);
115.5 (d; 2JFC = 21.6 Hz; C-10′’. C-12′’); 123.0 (C-9); 124.2 (C-14); 124.6 (C-6′’); 125.3 (C-8); 129.8 (C-15);
130.3 (d; 3JFC = 8.4 Hz; C-9′’. C-13′’); 132.1 (d; 4JFC = 3.1 Hz; C-8′’); 142.0 (C-2′’); 153.4 (C-13); 160.5
(C-11); 161.8 (d; 1JFC = 244.4 Hz; C-11′’); 171.4 (C-1′); 171.6 (C-4′. C(16)-COOCH3).
15N NMR (50.7 MHz; DMSO-d6) δ (ppm) −322.8 (N-4); −314.4 (N-1); −130.8 (N-5′’); −27.7 (N-3′’);
−18.7 (N-4′’).
ESI-HRMS: M + H = 704.30669 (delta = −3.3ppm; C37H43O8N5F). HR-ESI-MS-MS (CID = 35%; rel.
int. %): 686(100); 644(5); 397(22).
3.12. Synthesis of 17-Propargylvindoline (20)
17-Desacetylvindoline (9) [31] (600 mg, 1.4 mmol) and hexamethylphosphoramide (0.25 mL,
1.5 mmol) were dissolved in 18 mL of dry tetrahydrofuran under argon. The reaction mixture was
cooled to 0 ◦C, and a solution of 0.60 mL (1.6 mmol) 2.5 M n-butyllithium in hexane was added
dropwise via a syringe. After stirring for 5 min at 0 ◦C, propargyl bromide (0.156 mL, 1.4 mmol) was
added, while maintaining the temperature at 0 ◦ C. After stirring for 16 h at room temperature, the
mixture was diluted with 30 mL of distilled water and 60 mL of 10% Na2CO3 solution, then it was
extracted with dichloromethane (3 × 60 mL). The organic phase was dried over MgSO4, then the solvent
evaporated under reduced pressure. After preparative TLC (dichloromethane-methanol = 20:1) 185 mg
(32%) of a brown crystalline product (20) was obtained. Mp 80–88 ◦C. TLC (dichloromethane-methanol
= 20:1); Rf = 0,33. IR (KBr): 1080; 1245; 1502; 1735; 2931; 3276 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.49 (t; J = 7.3 Hz; 3H; H3-18); 0.93 (dq; J = 13.7. 7.3 Hz;
1H; Hx-19); 1.43 (dq; J = 13.7. 7.3 Hz; 1H; Hy-19); 2.11–2.19 (m; 2H; H2-6); 2.50–2.56 (m; 1H; Hx-5); 2.57
(s; 3H; N(1)-CH3); 2.60 (s; 1H; H-21); 2.77 (ddd; J = 16.1. 2.5. 1.5 Hz; 1H; Hx-3); 3.22–3.28 (m; 1H; Hy-5);
3.37 (ddd; J = 16.1. 4.9. 1.2 Hz; 1H; Hy-3); 3.38 (t; J = 2.4 Hz; 1H; H-3′); 3.44 (s; 1H; H-2); 3.68 (s; 1H;
H-17); 3.69 (s; 6H; C(16)-COOCH3. C(11)-OCH3); 4.20–4.27 (m; 2H; H2-1′); 5.46 (ddd; J = 10.2. 2.5. 1.2
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Hz; 1H; H-15); 5.78 (ddd; J = 10.2. 4.9. 1.5 Hz; 1H; H-14); 6.16 (d; J = 2.3 Hz; 1H; H-12); 6.26 (d; J = 8.2.
2.3 Hz; 1H; H-10); 7.02 (d; J = 8.2 Hz; 1H; H-9); 8.47 (s; 1H; C(16)-OH).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.7 (C-18); 32.1 (C-19); 38.4 (N(1)-CH3); 43.2 (C-20); 44.0
(C-6); 50.5 (C-3); 51.1 (C-5); 51.6 (C(16)-COOCH3); 51.9 (C-7); 55.0 (C(11)-OCH3); 60.7 (C-1′); 66.6 (C-21);
76.5 (C-3′); 79.9 (C-16); 81.1 (C-2′); 83.4 (C-2); 84.3 (C-17); 95.3 (C-12); 104.3 (C-10); 122.9 (C-9); 123.0
(C-14); 125.5 (C-8); 131.2 (C-15); 153.4 (C-13); 160.4 (C-11); 172.6 (C(16)-COOCH3).
ESI-HRMS: M + H = 453.23785 (delta = −1.2ppm; C26H33O5N2). HR-ESI-MS-MS (CID = 35%; rel.
int. %): 435(21); 397(45); 393(100); 188(32).
3.13. The Click Reaction of 17-Propargylvindoline (20) and 4-Fluorobenzyl-Azide (18)
205 mg (0.45 mmol) of 17-propargylvindoline (20), 72 mg (0.48 mmol) of 4-fluorobenzyl-azide,
24 mg (0.09 mmol) of triphenylphosphine and 9 mg (0.05 mmol) of copper (I) iodide were dissolved in
10 mL of dry toluene, then 0 24 mL (1.4 mmol) of DIPEA was added, and the reaction mixture was
stirred at reflux for 5 h. Then, 60 mL of toluene was added, and the mixture was washed with 75 mL of
distilled water, finally the aqueous phase was washed with another 25 mL of toluene. The organic
phase was dried over MgSO4, then the solvent evaporated under reduced pressure. After preparative
TLC (dichloromethane-methanol = 30:1) 126 mg (46%) of a yellow crystalline product (21) was obtained.
Mp 92–95 ◦C. TLC (dichloromethane-methanol = 30:1); Rf = 0,24. IR (KBr): 1085, 1224; 1245; 1502; 1736;
2837; 2946 cm−1.
1H NMR (799.7 MHz; DMSO-d6) δ (ppm) 0.50 (t; J = 7.3 Hz; 3H; H3-18); 0.98 (dq; J = 13.7. 7.3 Hz;
1H; Hx-19); 1.38 (dq; J = 13.7. 7.3 Hz; 1H; Hy-19); 2.13–2.17 (m; 2H; H2-6); 2.50–2.54 (m; 1H; Hx-5); 2.59
(s; 3H; N(1)-CH3); 2.61 (s; 1H; H-21); 2.74–2.78 (m; 1H; Hx-3); 3.21–3.25 (m; 1H; Hy-5); 3.32–3.36 (m;
1H; Hy-3); 3.44 (s; 1H; H-2); 3.66 (s; 3H; C(16)-COOCH3); 3.70 (s; 3H; C(11)-OCH3); 3.85 (s; 1H; H-17);
4.62.–4.68 (AB; J = 11.2 Hz; 2H; H2-1′); 5.42–5.45 (m; 1H; H-15); 5.56 (~s; 2H; H2-7′); 5.73 (ddd; J = 10.2.
5.0. 1.5 Hz; 1H; H-14); 6.17 (d; J = 2.3 Hz; 1H; H-12); 6.27 (dd; J = 8.2. 2.3 Hz; 1H; H-10); 7.02 (d; J = 8.2
Hz; 1H; H-9); 7.18–7.21 (m; 2H; H-10′. H-12′); 7.37–7.40 (m; 2H; H-9′. H-13′); 7.97 (s; 1H; H-6′); 8.43 (br
s; 1H; C(16)-OH).
13C NMR (201.1 MHz; DMSO-d6) δ (ppm) 7.7 (C-18); 32.5 (C-19); 38.4 (N(1)-CH3); 43.4 (C-20); 44.1
(C-6); 50.5 (C-3); 51.0 (C-5); 51.5 (C(16)-COOCH3); 51.7 (C-7′); 51.9 (C-7); 54.9 (C(11)-OCH3); 66.56
(C-1′); 66.60 (C-21); 80.0 (C-16); 83.4 (C-2); 83.6 (C-17); 95.3 (C-12); 104.2 (C-10); 115.5 (d; 2JFC = 21.6 Hz;
C-10′. C-12′); 122.9 (C-9); 123.0 (C-14); 123.6 (C-6′); 125.6 (C-8); 130.2 (d; 3JFC = 8.4 Hz; C-9′. C-13′);
131.1 (C-15); 132.3 (d; 4JFC = 3.0 Hz; C-8′); 144.7 (C-2′); 153.4 (C-13); 160.4 (C-11); 161.7 (d; 1JFC = 244.4
Hz; C-11′); 172.6 (C(16)-COOCH3).
15N NMR (81.0 MHz; DMSO-d6) δ (ppm) −322.7 (N-4); −314.1 (N-1); −131.5 (N-5′); −28.6 (N-3′);
-20.5 (N-4′).
ESI-HRMS: M + H = 604.29147 (delta = −2.5ppm; C33H39O5N5F). HR-ESI-MS-MS (CID = 35%; rel.
int. %): 586(18); 554(19); 544(82); 484(9); 415(100); 397(43); 377(27); 365(17); 355(28); 188(22).
3.14. N-Alkylation of Morpholine with 17-(4-Bromobutanoyloxy)vindoline (22)
17-(4-Bromobutanoyloxy)vindoline (22) [22,23] (120 mg, 0.21 mmol) was dissolved in 6 mL of
anhydrous DCM, and the stirring was started under argon. Then, 0,04 mL (0.43 mmol) of morpholine
was added. The reaction mixture was stirred at room temperature for 2 h, then at reflux for 11 h.
The mixture was then allowed to cool to room temperature. After the addition of 4 mL of DCM,
the mixture was extracted with 6 mL of 10% Na2CO3 solution. The aqueous phase was washed
with 6 mL of DCM, then the organic phase was washed with 6 mL of distilled water. The organic
phase was dried over MgSO4, then the solvent evaporated under reduced pressure. After preparative
TLC (dichloromethane-methanol = 15:1) 90 mg (74%) of a yellow oleic product (23) was obtained.
TLC (dichloromethane-methanol = 20:1); Rf = 0.27. IR (KBr): 2954, 2808, 1735, 1613, 1500, 1223, 1115,
1024 cm−1.
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1H NMR (499.9 MHz; CDCl3) δ (ppm) 0.48 (t; J = 7.4 Hz; 3H; H3-18); 1.14 (dq; J = 14.4. 7.4 Hz;
1H; Hx-19); 1.64 (dq; J = 14.4. 7.4 Hz; 1H; Hy-19); 1.78–1.84 (m; 2H; H2-3′); 2.27–2.41 (m; 6H; H2-6.
H2-4′. H2-2′); 2.41–2.48 (br m; 4H; H2-6′. H2-10′); 2.49–2.55 (m; 1H; Hx-5); 2.66 (s; 1H; H-21); 2.67 (s;
3H; N(1)-CH3); 2.82 (ddd; J = 16.0. 2.6. 1.6 Hz; 1H; Hx-3); 3.39–3.45 (m; 1H; Hy-5); 3.49 (ddd; J = 16.0.
4.9. 1.3 Hz; 1H; Hy-3); 3.67–3.73 (br m; 4H; H2-7′. H2-9′); 3.74 (s; 1H; H-2); 3.779 (s; 3H). 3.780 (s; 3H):
C(16)-COOCH3. C(11)-OCH3; 5.23 (ddd; J = 10.2. 2.6. 1.3 Hz; 1H; H-15); 5.46 (s; 1H; H-17); 5.84 (ddd;
J = 10.2. 4.9. 1.6 Hz; 1H; H-14); 6.07 (d; J = 2.3 Hz; 1H; H-12); 6.30 (dd; J = 8.2. 2.3 Hz; 1H; H-10); 6.89
(d; J = 8.2 Hz; 1H; H-9); 9.52 (br; 1H; C(16)-OH).
13C NMR (125.7 MHz; CDCl3) δ (ppm) 7.7 (C-18); 21.7 (br; C-3′); 30.8 (C-19); 31.8 (C-2′); 38.3
(N(1)-CH3); 42.9 (C-20); 44.1 (C-6); 51.1 (C-3); 52.0 (C-5); 52.2 (C(16)-COOCH3); 52.8 (C-7); 53.5 (br; C-6′.
C-10′); 55.4 (C(11)-OCH3); 57.9 (C-4′); 66.9 (br; C-7′. C-9′); 67.1 (C-21); 76.3 (C-17); 79.6 (C-16); 83.4
(C-2); 95.8 (C-12); 104.6 (C-10); 122.7 (C-9); 124.1 (C-14); 125.1 (C-8); 130.6 (C-15); 153.7 (C-13); 161.2
(C-11); 171.9 (C(16)-COOCH3); 173.2 (C-1′).
ESI-HRMS: M + H = 570.31692 (delta = −0.8 ppm; C31H44O7N3). HR-ESI-MS-MS (CID = 35%; rel.
int. %): 552(100); 415(2); 397(25); 188(1).
3.15. N-Alkylation of Piperazine with 17-(4-Bromobutanoyloxy)vindoline (22)
17-(4-Bromobutanoyloxy)vindoline (22) [22,23] (140 mg, 0.25 mmol) was dissolved in 6 mL of
anhydrous DCM, and the stirring was started under argon. Then, 43 mg (0.50 mmol) of piperazine was
added. The reaction mixture was stirred at reflux for 7 h. The mixture was then allowed to cool to room
temperature, and after the addition of a few DCM, the mixture was extracted with 6 mL of 10% Na2CO3
solution. The aqueous phase was washed with 6 mL of DCM, then the organic phase was washed with
6 mL of distilled water. The organic phase was dried over MgSO4, then the solvent evaporated under
reduced pressure. After preparative TLC (dichloromethane-methanol = 15:1) 47 mg (36%) of a pale
yellow crystalline product (24) was obtained. Mp 118–124 ◦C. TLC (dichloromethane-methanol = 15:1);
Rf = 0,05. IR (KBr): 2947, 2808, 1740, 1616 1502, 1246, 1170 cm−1.
The molecule is symmetric, it has two equivalent halves. The NMR assignment below applies to
the other half of the molecule as well.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.42 (t; J = 7.4 Hz; 6H; H3-18); 0.95 (dq; J = 13.9. 7.4 Hz;
2H; Hx-19); 1.48 (dq; J = 13.9. 7.4 Hz; 2H; Hy-19); 1.54–1.68 (m; 4H; H2-3′); 2.16–2.28 (m; 12H; H2-6.
H2-2′. H2-4′); 2.22–2.43 (br; 8H; H2-6′. H2-7′); 2.53–2.60 (m; 8H; N(1)-CH3. Hx-5); 2.64 (s; 2H; H-21);
2.79 (br d; J = 16.4 Hz; 2H; Hx-3); 3.25–3.31 (m; 2H; Hy-5); 3.41 (br dd; J = 16.4. 4.8 Hz; 2H; Hy-3);
3.54 (s; 2H; H-2); 3.63 (s; 6H; C(16)-COOCH3); 3.70 (s; 6H; C(11)-OCH3); 5.09 (br d; J = 10.2 Hz; 2H;
H-15); 5.19 (s; 2H; H-17); 5.81 (ddd; J = 10.2. 4.8. 1.2 Hz; 2H; H-14); 6.19 (d; J = 2.2 Hz; 2H; H-12); 6.28
(dd; J = 8.2. 2.2 Hz; 2H; H-10); 7.05 (d; J = 8.2 Hz; 2H; H-9); 8.75 (s; 2H; C(16)-OH).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 21.5 (C-3′); 30.3 (C-19); 31.3 (C-2′); 38.0
(N(1)-CH3); 42.4 (C-20); 43.6 (C-6); 50.4 (C-3); 51.1 (C-5); 51.6 (C(16)-COOCH3); 52.0 (C-7); 52.6 (C-6′.
C-7′); 55.0 (C(11)-OCH3); 56.6 (C-4′); 66.1 (C-21); 75.7 (C-17); 78.6 (C-16); 82.8 (C-2); 95.4 (C-12);
104.5 (C-10); 123.0 (C-9); 124.3 (C-14); 125.3 (C-8); 129.9 (C-15); 153.4 (C-13); 160.4 (C-11); 171.6
(C(16)-COOCH3); 172.4 (C-1′).
ESI-HRMS: M + H = 1051.57418 (delta = −0.8 ppm; C58H79O12N6). HR-ESI-MS-MS (CID = 35%;
rel. int. %): 1034(100); 1016(10); 655(2); 637(22); 619(11); 397(12).
3.16. N-Alkylation of N-Methylpiperazine with 17-(4-Bromobutanoyloxy)vindoline (22)
17-(4-Bromobutanoyloxy)vindoline (22) [22,23] (180 mg, 0.32 mmol) was dissolved in 8 mL
of anhydrous DCM, and the stirring was started under argon. Then, 0,072 mL (0.64 mmol) of
N-methylpiperazine was added. The reaction mixture was stirred at reflux for 12 h. The mixture
was then allowed to cool to room temperature, and after the addition of a few DCM, the mixture
was extracted with 6 mL of 10% Na2CO3 solution. The aqueous phase was washed with 6 mL of
DCM, then the organic phase was washed with 6 mL of distilled water. The organic phase was
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dried over MgSO4, then the solvent evaporated under reduced pressure. After preparative TLC
(dichloromethane-methanol = 15:1) 80 mg (43%) of a white crystalline product (25) was obtained.
Mp 65–70 ◦C. TLC (dichloromethane-methanol = 20:1); Rf = 0.06. IR (KBr): 2937, 2794, 1740, 1616, 1502,
1244, 1166 cm−1.
1H NMR (499.9 MHz; DMSO-d6) δ (ppm) 0.42 (t; J = 7.4 Hz; 3H; H3-18); 0.95 (dq; J = 14.0. 7.4 Hz;
1H; Hx-19); 1.49 (dq; J = 14.0. 7.4 Hz; 1H; Hy-19); 1.55–1.68 (m; 2H; H2-3′); 2.13 (s; 3H; H3-11′); 2.16–2.28
(m; 6H; H2-6. H2-2′. H2-4′); 2.17–2.44 (br; 8H; H2-7′. H2-9′. H2-6′. H2-10′); 2.53–2.61 (m; 4H; N(1)-CH3.
Hx-5); 2.66 (s; 1H; H-21); 2.79 (br d; J = 16.3 Hz; 1H; Hx-3); 3.25–3.31 (m; 1H; Hy-5); 3.41 (br dd; J = 16.3.
4.9 Hz; 1H; Hy-3); 3.54 (s; 1H; H-2); 3.64 (s; 3H; C(16)-COOCH3); 3.71 (s; 3H; C(11)-OCH3); 5.10 (br d;
J = 10.2 Hz; 1H; H-15); 5.19 (s; 1H; H-17); 5.81 (ddd; J = 10.2. 4.9. 1.2 Hz; 1H; H-14); 6.19 (d; J = 2.2 Hz;
1H; H-12); 6.28 (dd; J = 8.2. 2.2 Hz; 1H; H-10); 7.05 (d; J = 8.2 Hz; 1H; H-9); 8.76 (s; 1H; C(16)-OH).
13C NMR (125.7 MHz; DMSO-d6) δ (ppm) 7.5 (C-18); 21.5 (C-3′); 30.3 (C-19); 31.2 (C-2′); 38.0
(N(1)-CH3); 42.4 (C-20); 43.6 (C-6); 45.6 (C-11′); 50.4 (C-3); 51.1 (C-5); 51.6 (C(16)-COOCH3); 52.0 (C-7);
52.5 (C-6′. C-10′); 54.6 (C-7′. C-9′); 55.0 (C(11)-OCH3); 56.6 (C-4′); 66.1 (C-21); 75.7 (C-17); 78.7 (C-16);
82.8 (C-2); 95.4 (C-12); 104.5 (C-10); 123.0 (C-9); 124.3 (C-14); 125.3 (C-8); 129.9 (C-15); 153.4 (C-13); 160.5
(C-11); 171.6 (C(16)-COOCH3); 172.4 (C-1′).
EI-HRMS: M = 582.34230 (delta = 1.9 ppm; C32H46O6N4).
3.17. Cell Lines and Reagents
Human breast cancer cell lines MCF-7 and MDA-MB-231, and human cervical cancer HeLa cells
were purchased from ECCAC - European Collection of Cell Cultures, Salisbury, UK. SiHa cervical
cancer cells were obtained from the American Type Culture Collection (ATCC), Manassas, VA, USA.
Eagle’s minimum essential medium (EMEM), fetal bovine serum (FBS), penicillin–amphotericin B,
non-essential amino acids, trypsin, were purchased from Lonza Group Ltd. (Basel, Switzerland)
while Trypan blue solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
and dimethyl-sulfoxide (DMSO) were from Sigma-Aldrich Ltd. (Budapest, Hungary). All the cancer
cell lines were cultured in 75 cm2 flask (Orange Scientific, Hungary) in EMEM media according to the
distributor’s instructions, supplemented with 10% fetal bovine serum, 1% non-essential amino acids
and an antibiotic–antimycotic mixture. The cells were incubated in cultured conditions at 37 ◦C under
humidified atmosphere with 5% carbon dioxide CO2 [33].
3.18. Antiproliferative Assay
The antiproliferative activity of the prepared compounds was determined by colorimetric MTT
assay on a panel of human cancer cell lines isolated from breast (MCF-7 and MDA-MB-231) and cervical
(HeLa and SiHa) cancers as published before [34]. Briefly, the cells were seeded in 96-well microplates
with an initial cell density of 5 × 103 cells per well and incubated overnight to allow cells’ attachment
in the bottom of wells. Afterwards the cells were treated with mediums containing six different
concentrations (0.1, 0.3, 1, 3, 10, 30 µM) of the tested compounds and incubated for 72 h. We note that,
under the cell culture conditions, the highest DMSO content of the medium (0.3%) did not have any
substantial effect on cell proliferation. Subsequently, the cells were incubated with 44 µL of 5 mg/mL
MTT solution for 4 h. Then, the medium was discarded and the precipitated formazan crystals were
solubilized in 100 µL of DMSO by gently shaking for 60 min at 37 ◦C. Finally, absorbance was measured
at 545 nm wavelength by using a microplate reader. Antiproliferative activity was determined as
a percentage of inhibition compared to the untreated cell control. IC50 values, representing the 50%
inhibitory concentrations, were obtained from nonlinear regression using Graph Pad Prism 5.01 (Graph
Pad Software; San Diego, CA, USA). All in vitro tests were carried out in two separate experiments,
n = 5 each.
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4. Conclusions
A significant antitumor effect was presumed by connecting amino acids [(l)- or (d)-tryptophan]
and synthetic pharmacophores, such as a 1,2,3-triazole derivative, morpholine, piperazine and
N-methylpiperazine to the “monomer” vindoline (1), a natural compound of the Vinca alkaloid
family, which does not exhibit any antitumor effect by itself. The coupling of the key intermediates
10-aminovindoline (5) and 17-desacetylvindoline (9) with the aforementioned scaffolds resulted in
new Vinca alkaloid derivatives. a few of these compounds (11, 12, and 24) demonstrated promising
antitumor effect, and may be considered as promising leads, particularly against certain types of
cervical cancer. Our results suggest that it is possible to engineer vindoline (1) to become a real
anticancer drug by conjugating it with suitable pharmacophores.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/4/1010/s1,
1H and 13C NMR data of all the new compounds.
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